AI assistant
Revenio Group Oyj — Share Issue/Capital Change 2021
Mar 12, 2021
3236_rns_2021-03-12_6a6189a2-47bc-466d-82a0-bda479619802.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
REVENIO
Revenio Group Corporation: Increased number of shares entered into trade register
Revenio Group Corporation, Stock Exchange Release, March 12, 2021 at 9:00
INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER
Total of 16,335 new share subscriptions based on the company's 2015C stock options approved by the Board of Directors of Revenio Group Corporation on March 3, 2021, have been entered into the trade register today. The share subscription price under 2015C option rights was 12.48 EUR per share. The subscription period for 2015C options is May 31, 2019 – May 31, 2021.
After these subscriptions, the number of Revenio Group Corporation's shares and votes will rise to 26,675,287. The subscription price of the shares is recorded in their entirety in the reserve for invested unrestricted equity.
Revenio Group Corporation has applied for the listing of its new shares on the Nasdaq Helsinki in the same series as the company's existing shares. According to the current estimate, the new shares will be listed on March 15, 2021.
Revenio Group Corporation
Board of Directors
For further information, please contact:
Jouni Toijala, CEO, tel. +358 50 484 0085
[email protected]
www.revenio.fi
Revenio Group | Äyritie 22 | FI-01510 Vantaa
REVENIO
Revenio Group in brief
Revenio is an internationally operating health technology corporation and a globally leading supplier of ophthalmic devices. Revenio Group's eye diagnostics solutions include tonometers, retinal imaging apparatus and perimeters under the iCare brand. The main tool for the detection and diagnosis of glaucoma and its monitoring during treatment are intraocular pressure measurement (tonometry), retinal imaging, and visual field tests (perimetry).
The Revenio Group consists of Revenio Group Corporation, Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Done Medical Oy and Oscare Medical Oy.
In 2020, Revenio Group's net sales totalled EUR 61.1 million, with its net operating profit standing at EUR 17.1 million. Revenio Group Corporation's shares are listed on Nasdaq Helsinki with the trading code REG1V.
Attachments
Revenio Group Corporation: Increased number of shares entered into trade register
Revenio Group | Äyritie 22 | FI-01510 Vantaa